# Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

> **NCT00476216** · PHASE1 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 23 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Venous Thromboembolism

## Interventions

- **DRUG:** Combination of Arixtra with chemotherapy

## Key facts

- **NCT ID:** NCT00476216
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-12
- **Final completion:** 2013-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00476216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00476216, "Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00476216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*